Bringing Opportunities and Resources Together.
Portfolio - Biosciences
Ventria Bioscience, Inc.
Ventria Bioscience is a biotech company with a focus on human nutrition and human therapeutics. The Company's core technology is a plant-based protein production system called ExpressTec. Ventria completed construction of its bioprocessing facility in Junction City, Kansas and is expanding its operations in Kansas. Ventria's product pipeline is based on recombinant lactoferrin and lysozyme for use in medical foods, bioprocessing, cell culture and as a topical anti-infective. These proteins show promise as a supplement to oral rehydration therapy and promote the growth of healthy gut flora. Ventria invites other researchers to have access to its recombinant human lactoferrin and recombinant human lysozyme through a program called BioShare.
Contact: Ventria Bioscience
Phone: (800) 916-8311
www.ventria.com
CritiTech, Inc.
CritiTech conducts research and development into the production of fine-particle compounds. The Company is expanding its operations to become a developer and manufacturer of fine-particle pharmaceutical compounds servicing both the drug manufacturing and biotechnology industry.
Contact: Sam Campbell
Phone: (785) 841-7120
www.crititech.com
VasoGenix Pharmaceuticals, Inc.
VasoGenix Pharmaceuticals is a preclinical stage pharmaceutical company focused on the development and commercialization of synthetic agonist analogs of Calcitonin Gene Related Peptide (CGRP) to treat heart failure severe enough to require hospitalization. The Company’s technology was recently described by NIH reviewers as “highly innovative” and “a paradigm shifting therapy in the treatment of heart failure.” The analogs will be delivered intravenously and in a proprietary biodegradable controlled release delivery system, and are expected to reduce hospital length of stay and re-hospitalization rates, thereby saving the healthcare system billions annually.
Contact: Lee Southard
Phone: (913) 888-4773
www.vasogenix.net